WHO
REGULATORY UPDATE
43rd Invitation to manufacturers of Active Pharmaceutical Ingredients (API) to submit an Expression of Interest (EOI) for API evaluation to the WHO Prequalification Unit (PQT)
Published: 10/2/2026Detected: 8/18/2026
Summary preview
Expands the WHO API prequalification Expression of Interest (EOI) process to include additional APIs—Hydrocortisone (sodium succinate), Dactinomycin, Vincristine, and Cytarabine—aimed at identifying high-quality API…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountoncology
rare_diseases
pediatrics
hematology
manufacturing
quality
clinical
safety
labeling
#WHO prequalification
#API evaluation
Official Source Document Source Verified
Access the original document directly from WHO.
More from WHO
- New Deadline for Submission: Request for Quotations (RFQ) from interested Notified Bodies - WHO Prequalification Assessment for Medical Devices10/2/2026
- PQT/AMD newsletter - Q3 2026, Issue 54 is now available10/2/2026
- PQ Webinar: Launch of WHO Prequalification of Medical Devices10/2/2026
- New EUL listing10/2/2026
- Prequalification of In Vitro Diagnostics: Scope Expansion10/2/2026